Novo Nordisk receives EU approval of Levemir  

The European Commission has granted marketing authorisation for Novo Nordisk's new insulin drug

Healthcare company Novo Nordisk has been granted marketing authorisation by the European Commission for Levemir, a new long-acting insulin analogue for the treatment of diabetes. Novo Nordisk will launch Levemir in the UK later this month and in other European markets in the second half of 2004.


Levemir reportedly provides more consistent day-to-day control of blood glucose levels compared to conventional insulin preparations. With Levemir, Novo is the only manufacturer which has insulin analogues covering the full spectrum – fast-acting, slow-acting and mixed.


Novo Nordisk is a world leader in diabetes care. The company has the broadest product portfolio in the industry, including advanced products in the area of insulin delivery systems. Novo Nordisk employs approximately 18,800 people in 69 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. The news is reported in a stock exchange announcement on Copenhagen Stock Exchange website.


Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×